Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K

  • 28 Accesses

  • 11 Citations


C57BL mice inoculated with radiation leukemia virus (RadLV) develop preleukemic cells long before the onset of leukemia. These cells are potentially immunogenic but fail to elicit an immune response in the host because of the appearance of virus-specific suppressor T cells. We have studied the effect of polysaccharide K (PSK) on the generation of RadLV-specific cell-mediated immune responses in vitro. Long-term exposure to PSK in culture potentiated the ability of immunized T cells to respond to a RadLV-induced lymphoma. It also abrogated the suppressive activity of suppressor T cells and simultaneously boosted the ability of reactive T cells to respond. The dual immunostimulating activity of PSK resulted in the generation of T cytotoxic lymphocytes that could lyse lymphoma cells in vitro. The results suggest that PSK could be used as a prophylactic immune response modifier in preleukemia.

This is a preview of subscription content, log in to check access.


  1. 1.

    Ben-David Y, Kotler M, Yefenof E (1987) Leukemogenic, immunogenic and genetic properties of a thymotropic radiation leukemia virus. Int J Cancer 39: 492–497

  2. 2.

    Ben-David Y, Yefenof E, Kotler M (1987) Clonal analysis of radiation leukemia virus (RadLV) induced leukemic and preleukemic cells. Cancer Res 47: 6590–6594

  3. 3.

    Ebihara K, Minamishima Y (1984) Protective effect of biological response modifiers on murine cytomegalovirus infection. J Virol 51: 17–122

  4. 4.

    Enrke MJ, Reino JM, Eppolito C, Mihich E (1983) The effect of PS-K, a protein bound polysaccharide on immune responses against allogeneic antigens. Int J Immunopharmacol 5: 35–42

  5. 5.

    Haas M (1974) Continuous production of radiation leukemia virus in C57BL thymoma tissue culture lines: purification of the leukemogenic virus. Cell 1: 79–83

  6. 6.

    Haran-Ghera N (1978) Spontaneous and induced preleukemia cells in C57BL/6 mice: brief communication. J Natl Cancer Inst 60: 707–710

  7. 7.

    Haran-Ghera N, Peled A (1979) Induction of leukemia in mice by irradiation and radiation leukemia B virus variants. Adv Cancer Res 30: 45–83

  8. 8.

    Hosokawa M, Mizukoshi T, Sugawara M, Kobayashi H (1985) Therapeutic effects of PS-K and Busulfan on the recurrent and metastatic diseases after the surgical removal of 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice. Gann 76: 61–67

  9. 9.

    Kondo M, Kato H, Yokoe N, Matsumura N, Hotta T, Masasuke M (1978) Activation of the complement by immunostimulants, BCG, OK-432 (Picibanil), and PS-K (Krestin) in vitro. Gann 69: 699–702

  10. 10.

    Lieberman M, Kaplan HS (1959) Leukemogenic activity of filtrates from radiation induced lymphoid tumors of mice. Science 130: 387–388

  11. 11.

    Mizushima Y, Yuhki N, Hosokawa M, Kobayashi H (1982) Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PS-K and combined therapeutic effects of PS-K and cyclophosphamide on transplanted tumor in rats. Cancer Res 42: 5176–5180

  12. 12.

    Nomoto K, Yoshikumi C, Matsunaga K, Fujii T, Takeya K (1975) Restoration of antibody-forming capacities by PS-K in tumor-bearing mice. Gann 66: 365–374

  13. 13.

    Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Katano M, Yamamoto H, Kimura Y. Takesue M, Motoharu K, Nomoto K (1990) Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) adminstration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 31: 261–268

  14. 14.

    Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K (1984) Krestin (PSK). Cance Treat Rev 11: 131–155

  15. 15.

    Tsurku S, Nomoto K (1983) Effects of PSK on specific tumor immunity to syngeneic tumor cells. J Clin Lab Immunol 4: 215–219

  16. 16.

    Yefenof E, Ben-David Y (1983) Suppressor and reactive lymphocytes in radiation leukemia virus (RadLV)-induced leukemogenesis. Cancer Immunol Immunther 16: 48–52

  17. 17.

    Yefenof E, Ben-David Y (1986) Immunity and suppression in radiation and RadLV induced leukemogenesis. Leukemia Res 10: 797–801

  18. 18.

    Yefenof E, Zilcha D (1983) High and low leukemogeneic variants of radiation leukemia virus (RadLV) differ in ability to induce tumor specific immune suppression. Int J Cancer 30: 355–359

  19. 19.

    Yefenof E, Meidav A, Kedar E (1980) In vitro generation of cytotoxic lymphocytes against radiation and radiation leukemia virus (RadLV) induced tumors: III. Suppression of anti tumor immunity in vitro by lymphocytes of mice undergoing RadLV induced leukemogenesis. J Exp Med 152: 1473–1483

  20. 20.

    Yefenof E, Tchakirov R, Kedar E (1980) In vitro generation of cytotoxic lymphocytes against radiation and radiation leukemia virus (RadLV) induced tumors: I. Role of viral antigenicity. Cancer Immunol Immunother 8: 171–178

  21. 21.

    Yefenof E, Ben-David Y, Kotler M (1984) High-and low-leukemogenic variants of the radiation leukemia virus (RadLV): immunogenic, suppressive and genetic properties in relation to leukemogenic activity. Int J Cancer 34: 875–882

  22. 22.

    Yefenof E, Ben-David Y, Kotler M (1988) Preleukemic cells induced by RadLV are of an oligoclonal nature. Leukemia 2: 97–101

Download references

Author information

Correspondence to Eitan Yefenof.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yefenof, E., Einat, E. & Klein, E. Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K. Cancer Immunol Immunother 34, 133–137 (1991). https://doi.org/10.1007/BF01741348

Download citation

Key words

  • T cells
  • RadLV lymphoma
  • Immunomodulator PSK